Unity BiotechnologyUBX
Market Cap: $24.3M
About: Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
Employees: 19
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
8,000% more call options, than puts
Call options by funds: $81K | Put options by funds: $1K
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
1.01% less ownership
Funds ownership: 21.56% [Q1] → 20.55% (-1.01%) [Q2]
3% less funds holding
Funds holding: 40 [Q1] → 39 (-1) [Q2]
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
22% less capital invested
Capital invested by funds: $5.94M [Q1] → $4.66M (-$1.28M) [Q2]
50% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 12
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Rodman & Renshaw | 456%upside $8 | Buy Initiated | 22 Aug 2024 |
HC Wainwright & Co. Andrew Fein 46% 1-year accuracy 76 / 164 met price target | 456%upside $8 | Buy Reiterated | 8 Aug 2024 |